See all the latest news, blogs and updates from the medical sector.
MPS Society responds to key government consultations on support for children with complex needs
Over the past few weeks, the MPS Society has submitted responses to two important government consultations focused on education and support for children and young people with complex medical and additional needs.
"It's good to know I'm not alone": the value of our community spaces
Our online community spaces continue to grow, with more than 200 members in our WhatsApp communities and over 300 members in our Facebook community. We asked members about their experiences and the feedback was overwhelmingly positive.
Chiesi receives MHRA approval for additional dosing regimen of Elfabrio
We are pleased to share that Chiesi has received MHRA approval for an additional dosing regimen for pegunigalsidase alfa in adults stable with an enzyme replacement therapy (ERT).
Ayla's story | MPS Awareness Week 2026
This MPS Awareness Week, we hear Ayla’s story. Diagnosed with MPS I Hurler at the age of four, Ayla is at the heart of a close‑knit and outgoing family unit.
From hospital ward to centre stage: Sam’s Story inspires new play
We caught up with Sam in March and watched him in a play written by his mum and inspired by his time on a children’s ward.
Equity and quality in rare conditions
Improving equity and quality of care for people living with rare conditions continues to be a key priority across health and care systems. It is encouraging to see organisations such as NICE developing clear quality standards for rare diseases.
Benefits support and upcoming changes
We know that ongoing changes to the benefits system can feel unsettling and that many families are facing uncertainty as reforms are discussed and introduced over the coming years.
Together we can transform lives
Blue is the colour of our steely steppers all racing for rare. Head over to our fabulous fundraising blog to find out more!
Progress in MPS II and MPS III therapies
Clinical research in MPS continues to move at pace internationally, with a number of important regulatory developments over the past few months, particularly in MPS II Hunter and MPS III Sanfilippo.
Denali Therapeutics announces U.S. FDA approval of MPS II treatment
Following Denali's announcement that the FDA has approved an enzyme replacement therapy for the neurological aspects of MPS II, we recognise that our community may have questions.